CT-996
Roche
Oral small-molecule GLP-1 agonist in obesity Phase 2.
Selected study results
Early oral obesity studyMean body-weight changeBody weight decreased 7.3% · 4 weeks · Phase 1
Mean body-weight change · 4 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity without type 2 diabetes · Oral CT-996; dose not specified in this topline summary · N not included in this summary · Sponsor-reported 4-week result. Results & methods ↗
Short early study; longer-duration Phase 2 outcomes are needed.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: The Phase 2 obesity study NCT07081958 is completed in the October 26, 2026 registry update; no registry results are posted.
Next: Phase 2 obesity efficacy and safety results.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
CT-996 obesity program
Weight managementLonger-duration oral obesity evaluation.
